Telix Pharmaceuticals Limited (NASDAQ:TLX - Free Report) - Equities researchers at William Blair dropped their FY2025 earnings per share (EPS) estimates for shares of Telix Pharmaceuticals in a research report issued to clients and investors on Monday, July 14th. William Blair analyst A. Hsieh now forecasts that the company will post earnings of $0.49 per share for the year, down from their previous forecast of $0.83. William Blair has a "Outperform" rating on the stock. The consensus estimate for Telix Pharmaceuticals' current full-year earnings is $0.24 per share. William Blair also issued estimates for Telix Pharmaceuticals' FY2026 earnings at $0.65 EPS and FY2027 earnings at $0.88 EPS.
Other equities analysts have also recently issued research reports about the stock. Wedbush reissued an "outperform" rating and set a $22.00 price objective on shares of Telix Pharmaceuticals in a research report on Thursday, June 12th. HC Wainwright began coverage on shares of Telix Pharmaceuticals in a research report on Thursday, July 3rd. They issued a "buy" rating and a $23.00 price target for the company.
Read Our Latest Research Report on TLX
Telix Pharmaceuticals Price Performance
TLX stock traded up $0.09 during midday trading on Wednesday, reaching $16.23. 13,127 shares of the stock were exchanged, compared to its average volume of 28,888. The company has a fifty day moving average price of $16.48 and a 200 day moving average price of $16.95. Telix Pharmaceuticals has a 52 week low of $13.61 and a 52 week high of $30.36. The company has a current ratio of 2.78, a quick ratio of 2.66 and a debt-to-equity ratio of 0.99.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Telix Pharmaceuticals stock. Private Advisor Group LLC purchased a new stake in Telix Pharmaceuticals Limited (NASDAQ:TLX - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 10,140 shares of the company's stock, valued at approximately $170,000.
About Telix Pharmaceuticals
(
Get Free Report)
Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.
Further Reading
Before you consider Telix Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Telix Pharmaceuticals wasn't on the list.
While Telix Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
